296 related articles for article (PubMed ID: 37221577)
1. Fatty acids metabolism affects the therapeutic effect of anti-PD-1/PD-L1 in tumor immune microenvironment in clear cell renal cell carcinoma.
Lin H; Fu L; Li P; Zhu J; Xu Q; Wang Y; Mumin MA; Zhou X; Chen Y; Shu G; Yao G; Chen M; Lu J; Zhang L; Liu Y; Zhao Y; Bao J; Chen W; Luo J; Li X; Chen Z; Cao J
J Transl Med; 2023 May; 21(1):343. PubMed ID: 37221577
[TBL] [Abstract][Full Text] [Related]
2. Functional enrichment analysis of LYSET and identification of related hub gene signatures as novel biomarkers to predict prognosis and immune infiltration status of clear cell renal cell carcinoma.
Chen Y; He J; Jin T; Zhang Y; Ou Y
J Cancer Res Clin Oncol; 2023 Dec; 149(18):16905-16929. PubMed ID: 37740762
[TBL] [Abstract][Full Text] [Related]
3. Identification of fatty acid metabolism-related molecular subtype biomarkers and their correlation with immune checkpoints in cutaneous melanoma.
Xu Y; Chen Y; Jiang W; Yin X; Chen D; Chi Y; Wang Y; Zhang J; Zhang Q; Han Y
Front Immunol; 2022; 13():967277. PubMed ID: 36466837
[TBL] [Abstract][Full Text] [Related]
4. Computational construction of TME-related lncRNAs signature for predicting prognosis and immunotherapy response in clear cell renal cell carcinoma.
Zhou L; Fang H; Guo F; Yin M; Long H; Weng G
J Clin Lab Anal; 2022 Aug; 36(8):e24582. PubMed ID: 35808868
[TBL] [Abstract][Full Text] [Related]
5. Integrated analysis of single-cell and bulk transcriptome identifies a signature based on NK cell marker genes to predict prognosis and therapeutic response in clear cell renal cell carcinoma.
Wang K; Yu M; Zhang Z; Yin R; Chen Q; Zhao X; Yu H
Transl Cancer Res; 2023 May; 12(5):1270-1289. PubMed ID: 37304554
[TBL] [Abstract][Full Text] [Related]
6. Identification and verification of a novel anoikis-related gene signature with prognostic significance in clear cell renal cell carcinoma.
He Z; Gu Y; Yang H; Fu Q; Zhao M; Xie Y; Liu Y; Du W
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11661-11678. PubMed ID: 37402968
[TBL] [Abstract][Full Text] [Related]
7. Novel amino acid metabolism-related gene signature to predict prognosis in clear cell renal cell carcinoma.
Cheng X; Deng W; Zhang Z; Zeng Z; Liu Y; Zhou X; Zhang C; Wang G
Front Genet; 2022; 13():982162. PubMed ID: 36118874
[No Abstract] [Full Text] [Related]
8. Comprehensive analyses of A 12-metabolism-associated gene signature and its connection with tumor metastases in clear cell renal cell carcinoma.
Tan D; Miao D; Zhao C; Shi J; Lv Q; Xiong Z; Yang H; Zhang X
BMC Cancer; 2023 Mar; 23(1):264. PubMed ID: 36949462
[TBL] [Abstract][Full Text] [Related]
9. Identification of a claudin-low subtype in clear cell renal cell carcinoma with implications for the evaluation of clinical outcomes and treatment efficacy.
Zhang C; Li Y; Qian J; Zhu Z; Huang C; He Z; Zhou L; Gong Y
Front Immunol; 2022; 13():1020729. PubMed ID: 36479115
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic Utility of RNA-Seq for Evaluation of PD-L1 Expression in Clear Cell Renal Cell Carcinoma.
Sorokina M; Stupichev D; Lyu Y; Ramachandran A; Miheecheva N; Brown JH; Nomie K; Postovalova E; Bagaev A; Tsiper M; Hsieh JJ
Clin Genitourin Cancer; 2021 Dec; 19(6):e374-e381. PubMed ID: 34389275
[TBL] [Abstract][Full Text] [Related]
11. A New Signature That Predicts Progression-Free Survival of Clear Cell Renal Cell Carcinoma with Anti-PD-1 Therapy.
Lin J; Cai Y; Ma Y; Pan J; Wang Z; Zhang J; Liu Y; Zhao Z
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982415
[TBL] [Abstract][Full Text] [Related]
12. A novel necroptosis-related long noncoding RNA model for predicting clinical features, immune characteristics, and therapeutic response in clear cell renal cell carcinoma.
Zhang L; Chen Y; Hu W; Wu B; Ye L; Wang D; Bai T
Front Immunol; 2023; 14():1230267. PubMed ID: 37600792
[TBL] [Abstract][Full Text] [Related]
13. Development and validation of a combined hypoxia- and metabolism-related prognostic signature to predict clinical prognosis and immunotherapy responses in clear cell renal cell carcinoma.
Wu X; Xie W; Gong B; Fu B; Chen W; Zhou L; Luo L
Front Oncol; 2023; 13():1162846. PubMed ID: 38023248
[TBL] [Abstract][Full Text] [Related]
14. Solute carrier-related signature for assessing prognosis and immunity in patients with clear-cell renal cell carcinoma.
Bao W; Han Q; Guan X; Wang Z; Gu M
Oncol Res; 2023; 31(2):181-192. PubMed ID: 37304236
[TBL] [Abstract][Full Text] [Related]
15. Fatty acid metabolism-related lncRNAs are potential biomarkers for survival prediction in clear cell renal cell carcinoma.
Zhang MQ; Yang BZ; Wang ZQ; Guo S
Medicine (Baltimore); 2024 Feb; 103(8):e37207. PubMed ID: 38394500
[TBL] [Abstract][Full Text] [Related]
16. Programmed cell death ligand 1 and tumor-infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation.
Kawakami F; Sircar K; Rodriguez-Canales J; Fellman BM; Urbauer DL; Tamboli P; Tannir NM; Jonasch E; Wistuba II; Wood CG; Karam JA
Cancer; 2017 Dec; 123(24):4823-4831. PubMed ID: 28832979
[TBL] [Abstract][Full Text] [Related]
17. TRAF2 promotes M2-polarized tumor-associated macrophage infiltration, angiogenesis and cancer progression by inhibiting autophagy in clear cell renal cell carcinoma.
Xu Y; Li L; Yang W; Zhang K; Zhang Z; Yu C; Qiu J; Cai L; Gong Y; Zhang Z; Zhou J; Gong K
J Exp Clin Cancer Res; 2023 Jul; 42(1):159. PubMed ID: 37415241
[TBL] [Abstract][Full Text] [Related]
18. Transcriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell Carcinoma.
Denize T; Hou Y; Pignon JC; Walton E; West DJ; Freeman GJ; Braun DA; Wu CJ; Gupta S; Motzer RJ; Atkins MB; McDermott D; Choueiri TK; Shukla SA; Signoretti S
Clin Cancer Res; 2022 Sep; 28(18):4045-4055. PubMed ID: 35802667
[TBL] [Abstract][Full Text] [Related]
19. Higher programmed cell death 1 ligand 1 (PD-L1) mRNA level in clear cell renal cell carcinomas is associated with a favorable outcome due to the active immune responses in tumor tissues.
Ning XH; Gong YQ; He SM; Li T; Wang JY; Peng SH; Chen JC; Liu JY; Qi NN; Guo YL; Gong K
Oncotarget; 2017 Jan; 8(2):3355-3363. PubMed ID: 27926518
[TBL] [Abstract][Full Text] [Related]
20. Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma.
Motzer RJ; Powles T; Atkins MB; Escudier B; McDermott DF; Alekseev BY; Lee JL; Suarez C; Stroyakovskiy D; De Giorgi U; Donskov F; Mellado B; Banchereau R; Hamidi H; Khan O; Craine V; Huseni M; Flinn N; Dubey S; Rini BI
JAMA Oncol; 2022 Feb; 8(2):275-280. PubMed ID: 34940781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]